trending Market Intelligence /marketintelligence/en/news-insights/trending/MmM6KBrDHkFmAF18Tu7YBQ2 content esgSubNav
In This List

CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Bristol-Myers Squibb Co. said a panel of the European Medicines Agency recommended the approval of Yervoy for treating skin cancer in pediatric patients.

The backing from the EMA's Committee for Medicinal Products for Human Use covers the use of Yervoy, or ipilimumab, in unresectable or metastatic melanoma patients aged 12 years and older.

Bristol-Myers' Yervoy is already approved for multiple cancer indications. The monoclonal antibody works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.